

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

INSIDE INFORMATION PROPOSED PUBLIC ISSUANCE OF CORPORATE BONDS IN THE PRC

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of China Resources Pharmaceutical Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司) (“**CR Pharmaceutical Holdings**”), a wholly-owned subsidiary of the Company, has received the Approval on the Public Issuance of Corporate Bonds to Qualified Investors by China Resources Pharmaceutical Holdings Company Limited (Zheng Jian Xu Ke [2018] No. 2007) (the “**Approval**”) from the China Securities Regulatory Commission, approving the proposed public issuance of corporate bonds by CR Pharmaceutical Holdings to qualified investors in the People’s Republic of China (the “**PRC**”) in an aggregate principal amount of not more than RMB10 billion (the “**Corporate Bonds**”). The Corporate Bonds shall be issued in tranches, and the term of the Corporate Bonds (other than those which are renewable) shall not be more than 15 years.

If the proposed issuance of the Corporate Bonds proceeds, it is expected that the net proceeds raised therefrom will be used for the replenishment of working capital and repayment of borrowings of the Group.

The Company will make further announcement in relation to the proposed issuance of the Corporate Bonds as and when appropriate.

As the proposed issuance of the Corporate Bonds may or may not proceed, shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Executive Director

Shenzhen, 7 December 2018

As of the date of this announcement, the Board comprises Mr. FU Yuning as chairman and non-executive Director, Mr. WANG Chuncheng and Mr. LI Guohui as executive Directors, Mr. CHEN Rong, Mr. YU Zhongliang, Mr. WANG Shouye and Mr. LU Ruizhi as non-executive Directors, Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.